Melissa Palmer

6PUBLICATIONS
9CO-AUTHORS
Molecular targetsLiquid biopsiesBiomaterialsCancer geneticsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 20, 2024
Review article: Recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patients.

Anna Fettiplace, John Marcinak, Michael Merz

|Oct 25, 2023
Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum.

Melissa Palmer, David E Kleiner, Zachary Goodman

|Nov 26, 2019
Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease.

Melissa Palmer, Arie Regev, Keith Lindor

|Jun 25, 2019
Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice.

Kanita Salic, Robert Kleemann, Cynthia Wilkins-Port

|Feb 15, 2019
Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis.

Arie Regev, Melissa Palmer, Mark I Avigan

|Mar 18, 2018
A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis.

Melissa Palmer, Lee Jennings, Debra G Silberg

Pageof 1

Frequent Collaborators

4 joint publications

Arie Regev

2 joint publications

Arun J Sanyal

1 joint publications

Stephen A Harrison

1 joint publications

Raj Vuppalanchi